Zacks Research Has Strong Forecast for PCRX FY2024 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Analysts at Zacks Research upped their FY2024 earnings estimates for Pacira BioSciences in a report released on Wednesday, December 11th. Zacks Research analyst R. Department now expects that the company will earn $2.60 per share for the year, up from their prior forecast of $2.36. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.32 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q2 2025 earnings at $0.58 EPS, FY2025 earnings at $2.30 EPS, Q1 2026 earnings at $0.61 EPS and FY2026 earnings at $2.64 EPS.

A number of other research firms also recently weighed in on PCRX. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Royal Bank of Canada upped their target price on Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Pacira BioSciences in a report on Friday, November 8th. Barclays dropped their price objective on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. Finally, Jefferies Financial Group lifted their target price on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.50.

Pacira BioSciences Stock Up 0.1 %

Pacira BioSciences stock opened at $19.87 on Monday. The firm’s 50 day moving average price is $17.27 and its two-hundred day moving average price is $18.97. The firm has a market cap of $917.40 million, a PE ratio of -9.78 and a beta of 0.80. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $35.95. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

Hedge Funds Weigh In On Pacira BioSciences

Institutional investors have recently made changes to their positions in the business. Pacer Advisors Inc. grew its holdings in shares of Pacira BioSciences by 129.4% during the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock worth $74,681,000 after purchasing an additional 2,799,434 shares in the last quarter. Fort Washington Investment Advisors Inc. OH bought a new stake in shares of Pacira BioSciences during the second quarter worth $13,240,000. Assenagon Asset Management S.A. increased its stake in shares of Pacira BioSciences by 314.4% in the third quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock valued at $8,324,000 after buying an additional 419,656 shares in the last quarter. Doma Perpetual Capital Management LLC raised its holdings in shares of Pacira BioSciences by 71.8% in the second quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock valued at $28,632,000 after buying an additional 418,321 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Pacira BioSciences by 269.7% in the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock valued at $5,955,000 after buying an additional 288,662 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.